ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Extended Pleurectomy Decortication and Chemotherapy Versus Chemotherapy Alone for Pleural Mesothelioma (MARS 2): A Phase 3 Randomized Controlled Trial
Thursday, June 20, 2024
Submitted by
Source
Source Name: The Lancet Respiratory Medicine
In this phase three national, multicenter, UK randomized controlled trial, the authors seek to compare outcomes after extended pleurectomy decortication plus chemotherapy versus chemotherapy alone. The trial recruited patients between 2015 and 2021 from 26 UK hospitals, recruiting and randomly assigning patients with a 1:1 allocation ratio. In total 335 patients were randomized, 87 percent of which were male. The authors concluded that extended pleurectomy decortication was associated with a worse survival up to two years.